Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Status:
Completed
Trial end date:
2010-01-22
Target enrollment:
Participant gender:
Summary
This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered
as an intramuscular injection given every 4 weeks to subjects with measurable advanced
malignant melanoma. Study objectives included determination of the anticancer activity,
cellular and humoral immunogenicity, and safety and tolerability of the NY-ESO-1 ISCOM
vaccine administered alone or preceded by a single administration of low-dose
cyclophosphamide.